Humanigen Inc (HGENQ)

[cowtown jay]

In regards to my oft-wondered-about covid pneumonia reinfection rate in lenz-treated patients, which I think could be an absolute game-changer for Humanigen's lenzilumab, I learned last night that I may again have to re-phrase my question, and likely have to ask more than just one question. But just to get started, let me ask the following.

In patients diagnosed with covid pneumonia, and treated with lenzilumab, what is the recurrence rate of those patients presenting with SARS-CoV-2 nucleocapsid proteins after treatment? (I'll have to pin this post to remember how to ask that question).

As my question was originally phrased, I didn't know better than to exclude subsequent presentations of covid found in spike proteins. The studies I reviewed last night demonstrate that covid in the spike proteins has no relation to how well lenz prevents future infections. Rather, as I read the studies I will link, covid found in spike proteins is mRNA vaccine-induced. So lenz-treated patients who subsequently present with covid spike proteins, have no bearing on the efficacy of lenz.

Attached is an autopsy report of a 76 year old man, which was used as a case study. The patient had no history of covid, but the pathologist found covid spike proteins leading to the heart and brain. It's a fascinating study which, along with a different, un-related discussion concerning San Vincente in the Darian Pass, kept me up all night reviewing.

The presentation gets off to what might be perceived as a slow start, but don't fast forward past the 11 minute mark, of the 28 minute video.